Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) win the battle for Amylin (AMLN), agreeing to buy the diabetes drug maker for $31/share (10% premium to Friday's close). The total size of the deal is $7B, and includes about $3.4B from AZN, which will expand its diabetes collaboration with Bristol
Amylin closed 0.6 percent higher at $28.20 in New York. The San Diego-based company’s shares were at $15.88 on March 26, the day before it was reported Bristol-Myers had made an unsolicited offer of $22 a share. Bristol-Myers gained 2.5 percent yesterday to end the session at $35.95.
Amylin closed 0.6 percent higher at $28.20 in New York. The San Diego-based company’s shares were at $15.88 on March 26, the day before it was reported Bristol-Myers had made an unsolicited offer of $22 a share. Bristol-Myers gained 2.5 percent yesterday to end the session at $35.95.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
